-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Galectin Therapeutics to Neutral

Benzinga·12/27/2024 16:42:02
Listen to the news
HC Wainwright & Co. analyst Ed Arce downgrades Galectin Therapeutics (NASDAQ:GALT) from Buy to Neutral.